Parametrica Management’s Medifast MED Stock Holding History

Parametrica Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,052	Closed	-$351K	–	261
2022 Q1	$351K	Buy	+2,052	New	+$387K	0.26%	88
2021 Q4	–	Sell	-1,272	Closed	-$245K	–	74
2021 Q3	$245K	Buy	+1,272	New	+$313K	0.18%	54

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.46B AUM 71.13% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Parametrica Management's MED Position: Q2 2022 in Review

Parametrica Management sold out of Medifast (MED) in Q2 2022, closing a stake of 2,052 shares — an estimated $351K sold.

Parametrica Management first reported a position in MED in Q3 2021 and held it in 2 quarters. The position peaked at $351K in Q1 2022. 284 funds tracked by Wall St. Rank hold MED as of Q2 2022.

Parametrica Management reported no remaining Medifast position as of Q2 2022 after selling out during the quarter.
Parametrica Management sold 2,052 Medifast shares in Q2 2022, an estimated $351K.
Parametrica Management first reported a position in Medifast in Q3 2021 and held it in 2 quarters.
Parametrica Management's Medifast position peaked at $351K in Q1 2022.
284 funds tracked by Wall St. Rank held Medifast as of Q2 2022.

Based on Parametrica Management's 13F filing for Q2 2022, filed 22 Jul 2022.